Varda's body becomes a factor during a medical sequence in which
she receives eye injections for a disease causing gradual blindness.
In June 2015, she became the first patient in North America to
receive an eye injection of about half a million retinal progenitor cells.
Few participants who
received eye injections of ranibizumab had eye - related complications, such as an infection inside the eye likely caused by the injections, or worsening of a retinal detachment that existed prior to beginning treatment.
Not exact matches
Patients with age - related macular degeneration who
received seven or more
eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.
The volunteers, ranging in age from 20 to 88,
received injections under their retina of a particular type of
eye cell, retinal pigment epithelium (RPE) cells, which were derived from hESCs in the lab.
They were randomized into three treatment groups and
received the assigned study drug by
injection into the
eye until the DME resolved or stabilized.
They tested it in a rat model of ADRP and found that after 2 to 3 months,
eyes that had been injected with the virus - ribozyme combo contained 30 to 40 % more rod cells than
eyes that
received a dummy
injection.
Currently, patients
receive these drugs, which cut off the growth of blood vessels that interfere with sight, as an
injection into the
eye once a month.
In the first published results from a clinical trial using human embryonic stem cells, two legally blind patients who
received an
injection of hESC - derived cells in one
eye have experienced no harmful side effects and appear to have slightly better vision.
Slightly more than half (53 percent) of
eyes in the laser group
received Lucentis
injections to treat DME.
At approximately P100,
eyes receiving either hNPCctx (n = 21) or hNPCctx - GDNF (n = 9)
injections retained robust ERG responses (Figure 2).
In the placebo arm, GS010 will be administered as a single intravitreal
injection to the first affected
eye, while the fellow
eye will
receive a placebo
injection.
At approximately P100,
eyes receiving hNPCctx (n = 21)
injections performed significantly better than sham - operated (n = 4) or untreated (n = 29) control
eyes (0.50 ± 0.01 c / d vs. 0.22 ± 0.03 c / d (p < 0.001) or 0.14 ± 0.02 c / d (p < 0.001), respectively)(Figure 3).